Skip to main content

Table 2 Crude and world- and Europe standardized incidence rates (per 105 person-years) for the overall population and for each molecular subtype, by year, from 2007 to 2012

From: Trends in molecular subtypes of breast cancer: description of incidence rates between 2007 and 2012 from three French registries

Year of diagnosis 2007 2008 2009 2010 2011 2012
Crude incidence rate (IR)       
 Overall 170.99 166.88 159.45 177.99 170.83 171.37
 TN 15.88 16.80 14.23 13.70 16.28 16.48
 HR+/HER2+ 9.59 11.10 10.36 11.41 9.38 13.00
 HR+/HER2- 110.23 106.95 107.13 121.43 118.90 114.76
 HR-/HER2+ 5.65 5.28 5.65 6.75 6.59 6.45
World Standardized IR       
 Overall 116.84 113.77 109.67 119.35 114.59 113.89
 TN 11.96 13.00 10.43 9.85 11.22 12.00
 HR+/HER2+ 6.70 8.26 8.37 8.74 7.26 10.03
 HR+/HER2- 75.78 73.03 72.73 82.07 79.68 75.21
 HR-/HER2+ 4.10 4.08 4.53 5.00 4.94 4.48
Europe Standardized IR       
 Overall 154.27 149.78 142.02 157.86 150.87 149.10
 TN 15.35 15.95 13.11 12.52 13.85 14.85
 HR+/HER2+ 8.37 10.65 10.20 11.18 9.32 11.88
 HR+/HER2- 100.97 96.98 95.48 108.85 106.15 100.69
 HR-/HER2+ 4.90 4.99 5.35 6.33 6.09 5.61
  1. TN: Triple Negative; HR: Hormone Receptors; HER: Human epidermal growth factor
\